Navigation Links
Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
Date:10/2/2007

ISIS 325568 is an Antisense Drug Targeting Glucagon Receptor for Treatment

of Type 2 Diabetes

CARLSBAD, Calif., Oct. 2 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today it has earned $5 million from Ortho-McNeil, Inc. (OMI), a Johnson & Johnson company, for achieving the first development milestone of initializing the Phase 1 clinical trial of ISIS 325568.

The collaboration between Isis and OMI, announced on September 13, 2007, includes the licensing of two second-generation antisense drugs, ISIS 325568 and ISIS 377131, both of which represent novel approaches for the treatment of metabolic disease. ISIS 325568 was designed to selectively inhibit the production of glucagon receptor and has demonstrated improved glucose control in animal models of Type 2 diabetes.

"We are pleased to have achieved this milestone so early in our collaboration with Ortho-McNeil, Inc.," said Jeffrey Jonas, M.D., Executive Vice President, Isis Pharmaceuticals. "OMI will be providing all funding for this study, while Isis will be managing the study through to completion before handing all additional development responsibilities over to our partner."

ABOUT GLUCAGON RECEPTOR (GCGR), TARGET OF ISIS 325568

Glucagon is a hormone that opposes the action of insulin and stimulates the liver to produce glucose. In Type 2 diabetes, unopposed action of glucagon can lead to increased blood glucose levels. Reducing the expression of liver GCGR using antisense inhibitors, and thereby reducing excessive liver glucose production, is expected to lower blood glucose levels and help control Type 2 diabetes. In preclinical studies, antisense inhibitors of GCGR led to im
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Pelosi: Bush Veto of Stem Cell Bill Says No to the Hopes of Million of Families Across America
2. Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million Annually
3. MIV Therapeutics Announces Renowned Researcher to Detail Milestone Pre-Clinical Results at Prominent International Conference EuroPCR 2007
4. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
5. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
6. Baxter Announces Final Phase I/II Data and Initiation of Phase III Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... ,, PHILADELPHIA, Dec. 4 Teamster members employed ... are hard at work educating the public about the ... put Philadelphia,s blood supply at risk. More than ... picket line yesterday when their issues were ignored by ...
(Date:12/4/2009)... Corporation (Nasdaq: DYNT ) announced it has signed ... rehab supplies to Benchmark Physical Therapy with 65 clinics ... pleased to be named the sole-source supplier to Benchmark ... of sales and marketing at Dynatronics. "Benchmark is known ...
(Date:12/4/2009)... FOREST, Ill., Dec. 4 Hospira, Inc. (NYSE: ... medication delivery company, today announced the launch of its ... intravenous (I.V.) medications and solutions, and now offers a ... the award-winning, environmentally responsible VisIV product. The launch of ...
Breaking Medicine Technology:Striking Red Cross Workers Raise Public Awareness of Unsafe Working Conditions 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4The Healthcare Scoop Community Says 26apos 3BEye Care 26apos 3B 50306 1The Healthcare Scoop Community Says 26apos 3BEye Care 26apos 3B 50306 2The Healthcare Scoop Community Says 26apos 3BEye Care 26apos 3B 50306 3Access Pharmaceuticals Announces Commercial Launch of MuGard 28TM 29 in Greece by SpePharm 50303 1Access Pharmaceuticals Announces Commercial Launch of MuGard 28TM 29 in Greece by SpePharm 50303 2Access Pharmaceuticals Announces Commercial Launch of MuGard 28TM 29 in Greece by SpePharm 50303 3Air Methods Petitions NTSB for Reconsideration of Probable Cause Determination 50300 1Air Methods Petitions NTSB for Reconsideration of Probable Cause Determination 50300 2
(Date:12/6/2009)... feline DNA in virus , , SUNDAY, Dec. 6 (HealthDay News) ... be found in a tiger that lived thousands or millions ... the virus took on a bit of a tiger,s genetic ... in the virus to this day. That tiger, in fact, ... the virus that ultimately led to its infection of humans. ...
(Date:12/6/2009)... new study provides welcome news for patients with a ... , The condition is estimated to impact 62,000 Canadians ... abnormal clot forms in a vein and restricts the ... cases, the clot may detach from its point of ... causing a potentially fatal condition known as a pulmonary ...
(Date:12/5/2009)... NEW ORLEANS, Dec. 5 There have been significant ... leading experts continue to gain a better understanding of ... treatment options and provide patients with the best care. ... the American Society of Hematology explores optimal induction therapies ...
(Date:12/5/2009)... eliminate triggers, experts advise , , SATURDAY, Dec. 5 (HealthDay ... and asthma can have bad reactions to certain holiday ... sneezing and wheezing, according to the American College of ... allergic to live evergreens may choose to decorate with ...
(Date:12/5/2009)... unusual places, and to do everything from growing mushrooms, making wine to ... ... would have thought that your wine, water and vegetables would have come ... new line of turbines, for industry end users, not wind farms. ...
Breaking Medicine News(10 mins):Health News:AIDS May Date Back to Ancient Tiger 2Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8Health News:Keep Asthma, Allergies at Bay for the Holidays 2Health News:Distributor Announces New Applications for Wind Turbines 2Health News:Distributor Announces New Applications for Wind Turbines 3
... is what usually gets folks to this advanced age, ... -- Living longer, even past the 100-year mark, doesn,t ... spent in sickness or disability, Danish researchers report. ... lives despite their advanced age, the study found. , ...
... Inc. (OTC Bulletin Board: URGP, http://www.urigen.com ... development and,commercialization of treatments for urological disorders, ... has issued the first patent for the,use ... for,Painful Bladder Syndrome/Interstitial Cystitis (PBS/IC). Patent number ...
... for life reach 210,000 cups sold by Labor Day ... 2008, First-of-its-kind virtual ... ... over, but the,fight to eliminate pediatric cancer charges ahead. The world,s first,virtual lemonade stand, ...
... LANSING, Mich., Aug. 19 Afid Therapeutics, Inc.,announced today ... vivo,(whole animal) demonstrations of the efficacy of its new ... applications. The,in vivo and some of the in vitro ... laboratory. Heparin is a complex drug, which is used,beyond ...
... Favor Stronger Coverage for Wheelchairs,Oxygen, and Other Home Medical ... Nearly three out of,four (74 percent) American voters agree ... problem of rapidly increasing Medicare spending for,America,s seniors." Voters ... A national telephone survey of 1,000 American adults ...
... new product specifically to use with the Gerbig Cleanroom systems. ... ... Engineering, a designer, fabricator and installer of http://www.gerbig.com [cleanrooms ... the AireCell line of modular cleanrooms. The product is an ...
Other Medicine News:Health News:Living to 100 Doesn't Mean Living Poorly 2Health News:Living to 100 Doesn't Mean Living Poorly 3Health News:Urigen Announces Issuance of Key Patent for URG101 - A Novel Therapy to Treat Painful Bladder Syndrome/Interstitial Cystitis 2Health News:Urigen Announces Issuance of Key Patent for URG101 - A Novel Therapy to Treat Painful Bladder Syndrome/Interstitial Cystitis 3Health News:Make an Impact on Pediatric Cancer Research Before Summer's End: Try Some Virtual Lemonade! 2Health News:Make an Impact on Pediatric Cancer Research Before Summer's End: Try Some Virtual Lemonade! 3Health News:Afid Therapeutics Inc.'s New Anticoagulant Heparin Replacement Passes in Vivo Test 2Health News:Republican and Democratic Voters View Home Care as a Solution to Rising Medicare Spending, Harris Survey Finds 2Health News:Republican and Democratic Voters View Home Care as a Solution to Rising Medicare Spending, Harris Survey Finds 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: